Genotoxic action of cycloplatam, a new platinum antitumor drug, on mammalian cells in vivo and in vitro

Armen Nersesyan, Emanuela Perrone, Paola Roggieri, Claudia Bolognesi

Research output: Contribution to journalArticlepeer-review


Cycloplatam (CP), a new antitumor platinum compound of the second generation, was first synthesized in Russia. This drug shows less toxicity in vivo than the widely used cisplatin and carboplatin and a higher antitumor activity than carboplatin. CP is not nephrotoxic with respect to the platinum-based antitumor agents. CP is actually studied in clinical phase II trials in Russia and Armenia. Promising results were obtained in patients with lung, ovary, and prostate cancers. The aim of this work was to study the micronuclei (MN) inducing effect of CP in vivo in murine bone marrow cells and in human lymphocytes in vitro. The mutagenic activity of CP in bone marrow of mice was significantly lower than that of cisplatin at equitoxic doses. In human lymphocytes CP induced a dose-dependent increase of MN, beginning at a very low dose (0.1μM). Our results showed that CP is much less toxic and MN inducing in vivo in murine bone marrow than cisplatin. In vitro data evidenced that CP is more toxic and genotoxic to human cells than cisplatin. The evidence of a MN-induced activity of an antitumor drug suggests a potential risk for long-time survivors.

Original languageEnglish
Pages (from-to)132-137
Number of pages6
Issue number3
Publication statusPublished - 2003


  • Antineoplastic agent
  • Cisplatin
  • Cycloplatam
  • Micronucleus assay
  • Mutagenicity
  • Organoplatinum compounds

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Genotoxic action of cycloplatam, a new platinum antitumor drug, on mammalian cells in vivo and in vitro'. Together they form a unique fingerprint.

Cite this